Skip to main content
SpringerLink
Log in

Effect of azilsartan on myocardial remodeling after acute myocardial infarction

  • Research
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the effect of azilsartan on myocardial remodeling after acute myocardial infarction (AMI).

Methods

A total of 200 AMI patients under percutaneous coronary intervention (PCI) were selected from the Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University from Jan 2021 to Dec 2021. The subjects were randomly divided to take either azilsartan or benazepril. Serum C1q tumor necrosis factor-associated protein 1 (CTRP1) levels were detected in all subjects after admission, and the indices of left ventricular end-diastolic volume (LVEDV), left ventricular end-diastolic diameter (LVEDD), and left ventricular ejection fraction (LVEF) were measured by using echocardiography. At the follow-up of 6 months and 1 year after PCI, the differences in CTRP1 and echocardiogram indices between the two groups were compared, and the influencing factors of myocardial remodeling after acute myocardial infarction were analyzed.

Results

The levels of LVEDV and CTRP1 in all subjects at 6 months and 1 year after PCI were lower than those before discharge, and the LVEDV in the azilsartan group at 6 months and 1 year after PCI was lower than that in the benazepril group. An improvement in myocardial remodeling was obviously observed within 6 months after PCI, but the effect declined over time.

Conclusions

Azilsartan can improve myocardial remodeling after acute myocardial infarction. CTRP1 may become an effective target for the prevention and treatment of myocardial remodeling after acute myocardial infarction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Availability of data and material

Data are available from the corresponding author upon request.

References

  1. McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726

    Article  PubMed  CAS  Google Scholar 

  2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1789–1858

  3. Lindsey ML, Hall ME, Harmancey R et al (2016) Adapting extracellular matrix proteomics for clinical studies on cardiac remodeling post-myocardial infarction. Clin Proteomics 13:19

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ibanez B, James S, Agewall S et al (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2):119–177

    Article  PubMed  Google Scholar 

  5. Cokkinos DV, Belogianneas C (2016) Left ventricular remodelling: a problem in search of solutions. Eur Cardiol 11(1):29–35

    Article  PubMed  PubMed Central  Google Scholar 

  6. Weir RA, McMurray JJ, Velazquez EJ (2006) Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol 97(10a):13f–25f

    Article  PubMed  Google Scholar 

  7. Kelly DJ, Gershlick T, Witzenbichler B et al (2011) Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. Am Heart J 162(4):663–670

    Article  PubMed  Google Scholar 

  8. Konstam MA, Kramer DG, Patel AR et al (2011) Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 4(1):98–108

    Article  PubMed  Google Scholar 

  9. Chen X-Y, He Y, Chen J-Y (2023) Pharmacological effects and mechanisms of Gastrodia elata and its active ingredients in the treatment of cardiovascular diseases. Tradit Med Res 8:49–54

    Article  Google Scholar 

  10. Chang Y, Wei W (2015) Angiotensin II in inflammation, immunity and rheumatoid arthritis. Clin Exp Immunol 179(2):137–145

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Marchesi C, Paradis P, Schiffrin EL (2008) Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 29(7):367–374

    Article  PubMed  CAS  Google Scholar 

  12. Fung ML (2014) The role of local renin-angiotensin system in arterial chemoreceptors in sleep-breathing disorders. Front Physiol 5:336

    Article  PubMed  PubMed Central  Google Scholar 

  13. Gu Y, Ding Y, Zhang X et al (2022) Secreted frizzled-related protein 3 alleviated cardiac remodeling induced by angiotensin II via inhibiting oxidative stress and apoptosis in mice. Eur J Pharmacol 934:175303

    Article  PubMed  CAS  Google Scholar 

  14. Gu Y, Zhang S, Chen X et al (2022) LongShengZhi alleviated cardiac remodeling via upregulation microRNA-150-5p with matrix metalloproteinase 14 as the target. J Ethnopharmacol 291:115156

    Article  PubMed  CAS  Google Scholar 

  15. Yalta K, Yilmaz MB, Yalta T et al (2020) Late versus early myocardial remodeling after acute myocardial infarction: a comparative review on mechanistic insights and clinical implications. J Cardiovasc Pharmacol Ther 25(1):15–26

    Article  PubMed  Google Scholar 

  16. Zaliaduonyte-Peksiene D, Simonyte S, Lesauskaite V et al (2014) Left ventricular remodelling after acute myocardial infarction: impact of clinical, echocardiographic parameters and polymorphism of angiotensinogen gene. J Renin Angiotensin Aldosterone Syst 15(3):286–293

    Article  PubMed  CAS  Google Scholar 

  17. Gu Y, Hu X, Ge PB et al (2021) CTRP1 aggravates cardiac dysfunction post myocardial infarction by modulating TLR4 in macrophages. Front Immunol 12:635267

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Westman PC, Lipinski MJ, Luger D et al (2016) Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 67(17):2050–2060

    Article  PubMed  Google Scholar 

  19. Van Linthout S, Tschöpe C (2017) Inflammation - cause or consequence of heart failure or both?. Curr Heart Fail Rep 14(4):251–265

    Article  PubMed  PubMed Central  Google Scholar 

  20. Wu L, Gao L, Zhang D et al (2018) C1QTNF1 attenuates angiotensin II-induced cardiac hypertrophy via activation of the AMPKa pathway. Free Radic Biol Med 121:215–230

    Article  PubMed  CAS  Google Scholar 

  21. de Araújo AA, Varela H, de Medeiros CA et al (2015) Azilsartan reduced TNF-α and IL-1β levels, increased IL-10 levels and upregulated VEGF, FGF, KGF, and TGF-α in an oral mucositis model. PLoS ONE 10(2):e0116799

    Article  PubMed  PubMed Central  Google Scholar 

  22. Kim KY, Kim HY, Kim JH et al (2006) Tumor necrosis factor-alpha and interleukin-1beta increases CTRP1 expression in adipose tissue. FEBS Lett 580(16):3953–3960

    Article  PubMed  CAS  Google Scholar 

  23. Gu Y, Zhang X, Zhang XW et al (2022) Correlation between serum Level of C1q/TNF-related protein 1 and prognosis of patients with acute ST segment elevation myocardial infarction. Mol Cardiol China 22(1):4427–4431

    Google Scholar 

Download references

Funding

This study was supported by the China Heart House-Chinese Cardiovascular Association HX fund (2022-CCA-HX-008) and Innovative Key Talents’ Project of The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University (ZC202203).

Author information

Authors and Affiliations

  1. Department of Cardiology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, Jiangsu, 223300, China

    Jing Wang, Ying Ding, Yi-Ren Yao, Hong-Yang Liu & Yang Gu

Authors
  1. Jing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ying Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yi-Ren Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hong-Yang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yang Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

G.Y. contributed to the conception and design of the experiments; W.J., D.Y., and Y.Y.R. carried out the experiments; D.Y., Y.Y.R., and L.H.Y. analyzed the experimental results and revised the manuscript; and W.J. and G.Y. wrote and revised the manuscript.

Corresponding author

Correspondence to Yang Gu.

Ethics declarations

Ethics approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University (KY-2022-137-01).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

The manuscript does not contain figures or other images with personal data.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, J., Ding, Y., Yao, YR. et al. Effect of azilsartan on myocardial remodeling after acute myocardial infarction. Eur J Clin Pharmacol 80, 223–230 (2024). https://doi.org/10.1007/s00228-023-03595-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-023-03595-0

Keywords

Search

Navigation